AI Article Synopsis
- Direct oral anticoagulants (DOACs) are becoming increasingly viable options for treating and preventing blood clots in children, thanks to new trials and the recent approval of drugs like dabigatran and rivaroxaban for pediatric use.
- Despite the growing adult data, there is still a lack of concrete real-world evidence on how well these drugs work for children who don’t fit the profiles used in clinical trials, raising concerns about their use in certain cases.
- The review highlights the specific data relevant to pediatrics, identifies areas needing more research, and discusses important practical considerations for effectively using DOACs in pediatric patients.
Article Abstract
Direct oral anticoagulants (DOACs) provide an attractive alternative for the management and prevention of thrombosis in pediatric patients. With multiple ongoing and published pediatric trials and recent regulatory approval of dabigatran and rivaroxaban, the landscape of pediatric anticoagulation is rapidly changing. However, as pediatricians gain experience with these drugs, it is important to be mindful of pediatric-specific considerations that may limit the use of DOACs in certain children and adolescents. While there is increasing adult data and experience, there is a paucity of real-world evidence to guide the use of these drugs in children who would not have met clinical trial inclusion criteria. In this mini review, we summarize pediatric specific data, areas for future research, and practical considerations for the use of DOACs in children and adolescents.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010784 | PMC |
| http://dx.doi.org/10.3389/fped.2022.860369 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!